KALV logo

KALV
KalVista Pharmaceuticals Inc

3,126
Mkt Cap
$1.37B
Volume
5.12M
52W High
$26.76
52W Low
$9.83
PE Ratio
-6.66
KALV Fundamentals
Price
$26.65
Prev Close
$26.66
Open
$26.66
50D MA
$18.59
Beta
0.85
Avg. Volume
5.02M
EPS (Annual)
-$3.23
P/B
-500.38
Rev/Employee
$267,698.18
$806.04
Loading...
Loading...
News
all
press releases
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV...
Business Wire·2d ago
News Placeholder
More News
News Placeholder
KalVista Pharmaceuticals (NASDAQ:KALV) Rating Lowered to "Neutral" at HC Wainwright
HC Wainwright cut shares of KalVista Pharmaceuticals from a "buy" rating to a "neutral" rating and set a $27.00 price target on the stock. in a research report on Friday...
MarketBeat·2d ago
News Placeholder
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Rating Lowered by JonesTrading
JonesTrading lowered KalVista Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Thursday...
MarketBeat·2d ago
News Placeholder
KalVista Pharmaceuticals (NASDAQ:KALV) Given "Hold" Rating at Needham & Company LLC
Needham & Company LLC reiterated a "hold" rating on shares of KalVista Pharmaceuticals in a report on Thursday...
MarketBeat·3d ago
News Placeholder
KalVista Pharmaceuticals (NASDAQ:KALV) Sees Large Volume Increase - Here's Why
KalVista Pharmaceuticals (NASDAQ:KALV) Sees Unusually-High Trading Volume - Should You Buy...
MarketBeat·3d ago
News Placeholder
Are KALV, TBRG, UNF, ESQ Obtaining Fair Deals for their Shareholders?
Are KALV, TBRG, UNF, ESQ Obtaining Fair Deals for their Shareholders? Are KALV, TBRG, UNF, ESQ Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, April 29, 2026 Insiders may stand to...
PR Newswire·4d ago
News Placeholder
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement
KalVista Pharmaceuticals (NASDAQ:KALV), a developer of oral therapies for rare diseases, closed Wednesday at $26.67, up 38.62%. The stock moved higher after news that Italy's Chiesi Group will acquire KalVista for $27 per share in cash. Investors are watching deal closing risks a...
Nasdaq News: Markets·4d ago
News Placeholder
Small Cap Stocks To Add to Your Watchlist - April 29th
KalVista Pharmaceuticals, Direxion Daily MU Bull 2X Shares, and POET Technologies are the three Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stocks are shares of publicly traded companies with relatively small market capitalizationstypically roughly bet...
MarketBeat·4d ago
News Placeholder
Medical Stocks To Consider - April 29th
Arcellx, UnitedHealth Group, Eli Lilly and Company, KalVista Pharmaceuticals, and AbbVie are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies whose primary business is in healthcare, including pharmaceutica...
MarketBeat·4d ago
News Placeholder
Promising Pharmaceutical Stocks To Research - April 29th
Eli Lilly and Company, KalVista Pharmaceuticals, AbbVie, Regeneron Pharmaceuticals, and Teva Pharmaceutical Industries are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, devel...
MarketBeat·4d ago
<
1
2
...
>

Latest KALV News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.